We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 0.55% | 27.40 | 27.00 | 28.90 | 28.00 | 27.40 | 27.40 | 10,152 | 16:35:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 66.64M | -10.1M | -0.0222 | -12.61 | 127.38M |
TIDMEKF
RNS Number : 2565I
EKF Diagnostics Holdings PLC
10 December 2020
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Result of General Meeting
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that at the General Meeting held earlier today, the ordinary resolution seeking Shareholders' approval to distribute the Company's entire holding of A Ordinary Shares in Trellus Health Limited by way of a dividend in specie to EKF Shareholders, was duly passed.
The Votes were cast as follows:
Resolutions For Against Withheld 1 278,311,319 99.97% 76,472 0.03% 2,736 ---------------- ----------- ----------- ----------- -------------
Further announcements on the dividend will be made in due course.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com Christopher Mills, Non-executive Chairman Tel: +44 (0) 29 2071 0570 Julian Baines, CEO Richard Evans, FD & COO N+1 Singer Tel: 020 7496 3000 Aubrey Powell / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking) Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com Paul McManus / Lianne Cawthorne Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ROMXBLFFBLLBFBD
(END) Dow Jones Newswires
December 10, 2020 08:09 ET (13:09 GMT)
1 Year Ekf Diagnostics Chart |
1 Month Ekf Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions